Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
Author Department
Internal Medicine; Pulmonary/Critical Care Medicine; Medicine
Document Type
Article, Peer-reviewed
Publication Date
4-2021
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/- oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and others require fairly high daily oral corticosteroid dosing to achieve control, which in turn may induce the well-known effects of long term steroid use. The anti-interleukin drugs have been reported to help improve daily symptoms and reduce steroid requirements. Much of the literature highlights the benefit of omalizumab. We present a case of dupilumab as add-on therapy in a patient with ABPA, which allowed us to reduce daily steroid dosage.
Recommended Citation
Ali M, Green O. Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis. Oxf Med Case Reports. 2021 Apr 28;2021(4):omaa029. doi: 10.1093/omcr/omaa029.
PMID
33948179